4.10 Results Delivery & Long-Term Follow-Up
Key Takeaways
- Results delivery is a structured counseling process: prepare, disclose clearly, pause for emotion, explain meaning/limitations, negotiate next steps, and plan follow-up—not a one-way lab readout.
- SPIKES-adjacent structure (setting, perception, invitation, knowledge, emotion, summary/strategy) adapts well to genetic disclosures when paired with genetics-specific content (inheritance, cascade, reclassification).
- VUS disclosure must state uncertainty explicitly, avoid treating VUS as pathogenic for medical or cascade decisions, and include recontact/reanalysis plans when appropriate.
- Long-term follow-up includes medical management handoffs, cascade testing outreach planning, psychosocial check-ins, and pathways for reclassification updates.
- Board items often test pacing after bad news and correct framing of VUS versus pathogenic results.
Why results delivery is scored separately from “knowing the genetics”
You can interpret an ACMG classification correctly and still fail the counseling task if you flood a shocked parent with exon numbers, skip emotion, mis-sell a VUS as actionable, or end without a cascade and recontact plan. Domain 4B expects results delivery and long-term follow-up as deliberate skills: how news is given, how meaning is co-constructed, and how care continues after the visit.
A SPIKES-adjacent structure adapted to genetics
Oncology’s SPIKES protocol is a useful scaffold; genetics adds inheritance, reproductive implications, and family communication.
| Step | SPIKES idea | Genetics adaptation |
|---|---|---|
| S — Setting | Privacy, right people present, minimize interruptions | Confirm modality privacy; ask whom they want present; silence phones; interpreter ready |
| P — Perception | Elicit what they already believe/know | “What have you been told to expect from this test?” Correct misconceptions gently later |
| I — Invitation | Ask how much detail they want now | Some want full gene lists; others need headline first—contract depth and pace |
| K — Knowledge | Give information in small chunks | Lead with bottom line (pathogenic / negative / VUS), then inheritance, risks, limitations |
| E — Emotion | Respond to affect with empathy | Silence, reflection, tissues; do not race to cascade logistics while sobbing peaks |
| S — Summary / Strategy | Plan next steps | Medical referrals, screening, reproductive options, cascade plan, follow-up timing, recontact |
Breaking bad news: practical pacing
- Warn shot: “I have the results, and they are not what we hoped” (when accurate).
- Clear headline: “The test found a pathogenic variant in GENE that explains the cardiomyopathy in your family.”
- Pause. Let silence work.
- Check in: “What is going through your mind?”
- Layered education: inheritance → personal implications → relatives → management → uncertainties.
- Written summary and scheduled follow-up—memory for facts drops after emotional shock.
Avoid starting with methodology lectures (“Next-generation sequencing of 87 genes…”) before the headline. Avoid false reassurance (“At least we have an answer”) when grief is primary—validation first.
Result-type playbooks
| Result type | Disclosure emphasis | Follow-up essentials |
|---|---|---|
| Pathogenic / likely pathogenic (P/LP) | Diagnosis/risk explanation; management; inheritance; cascade | Specialty referrals; screening calendar; family letter offer; psychosocial support |
| Negative (with residual risk) | What was ruled out vs not; residual risk; any further testing | When to revisit testing as technology/indication evolves |
| VUS | Not proven disease-causing; usually not used for predictive testing of healthy relatives; may be reinterpreted | Recontact policy; segregation studies if indicated; avoid irreversible decisions based on VUS alone |
| Secondary / unexpected findings | Re-contract; separate from primary indication; consent context | Extra time; ethics/consult as needed; careful documentation |
| Incidental carrier / pharmacogenetic | Distinguish from diagnostic finding | Reproductive counseling or medication implications as relevant |
VUS disclosure—high-yield precision
Clients hear “variant” and think “mutation = disease.” Explicit language matters:
- “This result is a variant of uncertain significance. Laboratories and clinicians do not have enough evidence to say it causes disease.”
- “We do not typically test healthy relatives for a VUS to predict their future risk the way we would for a known pathogenic variant.”
- “We will discuss whether additional information (family testing for segregation, data updates) could help later.”
- Document client understanding and any disagreement with recommendations.
Trap answers treat VUS like P/LP for mastectomy decisions or urge all cousins to test for the VUS tomorrow.
Cascade follow-up planning
Cascade testing turns one result into family risk reduction—when the variant is clinically actionable.
| Planning element | Counselor actions |
|---|---|
| Who is at risk | Review pedigree; prioritize first-degree then extend as indicated |
| What to tell | Offer family letters with gene, variant nomenclature, lab, and counseling contacts—client controls disclosure timing |
| How to access | Site-specific testing vs familial variant test; insurance navigation pointers |
| Barriers | Estrangement, stigma, distance, language—problem-solve without forcing disclosure |
| Documentation | Note which relatives discussed; client’s communication plan; materials provided |
Long-term follow-up is not only cascade: children aging into adult consent, pregnancy planning years later, reclassification letters, and surveillance adherence checks.
Long-term follow-up architecture
Think beyond “call if questions”:
- Near-term (days–weeks): Emotional processing visit/call; clarify questions after shock; confirm appointments with cardiology/oncology/etc.
- Medium-term (months): Cascade progress; adherence to screening; reproductive planning if relevant.
- Long-term (years): Reanalysis/reclassification pathways; updated guidelines; transitioning adolescents to adult care.
Institutions vary on recontact obligations; exam-wise, recognize that discussing how updates would reach the client is part of good disclosure, especially for VUS and evolving gene–disease relationships.
Integrated scenarios
Scenario A — pediatric diagnosis: Parents freeze after hearing “pathogenic.” Best next move is empathic presence and invitation for questions—not immediately listing reproductive recurrence percentages unless they ask or contracting indicates readiness.
Scenario B — VUS in a cancer panel: Client asks, “Should my sister get a double mastectomy?” Answer clarifies VUS should not drive that decision; sister may still need counseling based on family history/empiric risk.
Scenario C — negative panel, strong history: Emphasize residual risk and empiric management; plan follow-up if new genes/methods arise; avoid “you’re in the clear forever.”
Scenario D — telephonic P/LP disclosure already done poorly elsewhere: Re-contract a dedicated disclosure/counseling visit; assess understanding and distress; rebuild strategy and cascade plan.
Common traps
- Method dump before headline.
- No pause after bad news.
- Managing VUS as pathogenic for cascade predictive testing.
- Ending without written summary or timed follow-up.
- Taking over family disclosure against the client’s paced plan without an applicable duty-to-warn framework (ethics domain nuance).
Quick exam checklist
- Setting and perception checked?
- Headline clear; emotion addressed?
- Result class (P/LP, neg, VUS) framed correctly?
- Strategy includes medical next steps, cascade as appropriate, and longitudinal recontact/follow-up?
Immediately after disclosing a pathogenic variant that confirms a child’s suspected syndrome, the parents are silent and tearful. What is the counselor’s best next action?
A multigene panel returns a VUS in a moderate-penetrance gene. The client asks whether all siblings should be tested for that same VUS next week to “know if they are safe.” What is the most appropriate counseling emphasis?
Which element best completes a genetics-adapted “summary/strategy” step after a pathogenic hereditary cancer result?
A client received a brief phone message that results were “abnormal” and arrives panicked for a same-day visit. Using a SPIKES-adjacent approach, what should the counselor do early in the session?